Related references
Note: Only part of the references are listed.The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset in patients with Li-Fraumeni syndrome
Mariette Renaux-Petel et al.
FAMILIAL CANCER (2014)
DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer
D-W Wu et al.
ONCOGENE (2014)
Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649)
Stian Knappskog et al.
ONCOTARGET (2014)
Hormone Replacement Therapy in Females Can Decrease the Risk of Lung Cancer: A Meta-Analysis
Yanwen Yao et al.
PLOS ONE (2013)
Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk
Qiang Fu et al.
TUMOR BIOLOGY (2013)
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
Merete Bjornslett et al.
BMC CANCER (2012)
The p53 mRNA-Mdm2 Interaction Controls Mdm2 Nuclear Trafficking and Is Required for p53 Activation following DNA Damage
Madhavsai Gajjar et al.
CANCER CELL (2012)
Sex Differences and Sex Steroids in Lung Health and Disease
Elizabeth A. Townsend et al.
ENDOCRINE REVIEWS (2012)
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer
Stian Knappskog et al.
EUROPEAN JOURNAL OF CANCER (2012)
Murine double minute clone 2 309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience
Piotr Piotrowski et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2012)
MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer
Brid M. Ryan et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: A meta-analysis
Guoyuan Liu et al.
INTERNATIONAL JOURNAL OF UROLOGY (2012)
MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis
Erjiang Zhao et al.
MOLECULAR BIOLOGY REPORTS (2012)
An integrated map of genetic variation from 1,092 human genomes
David M. Altshuler et al.
NATURE (2012)
MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
Yan Wan et al.
BMC CANCER (2011)
The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians
Stian Knappskog et al.
CANCER CELL (2011)
MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis
Fang Fang et al.
MEDICAL ONCOLOGY (2011)
Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis
Konstantinos P. Economopoulos et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Surface Plasmon Resonance Study of Cooperative Interactions of Estrogen Receptor α and Transcriptional Factor Sp1 with Composite DNA Elements
Siew Jun Neo et al.
ANALYTICAL CHEMISTRY (2009)
MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians
Xian-Hua Gui et al.
EUROPEAN JOURNAL OF CANCER (2009)
Cigarette Smoking, MDM2 SNP309, Gene-Environment Interactions, and Lung Cancer Risk: A Meta-Analysis
Jianling Bai et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES (2009)
Gender-Associated Differences in Lung Cancer: Clinical Characteristics and Treatment Outcomes in Women
Seema Harichand-Herdt et al.
SEMINARS IN ONCOLOGY (2009)
ATM gene mutations result in both recessive and dominant expression phenotypes of genes and MicroRNAs
Denis A. Smirnov et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism
Fiona E. M. Paulin et al.
BMC CANCER (2008)
Cohort Profile: Cohort of Norway (CONOR)
Oyvind Naess et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2008)
MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility:: Evidence from 21 case-control studies
Zhibin Hu et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
MDM2 SNP309 and cancer risk: a combined analysis
Stefan Wilkening et al.
CARCINOGENESIS (2007)
Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility?: A large pooled series from the breast cancer association consortium
Marjanka K. Schmidt et al.
CANCER RESEARCH (2007)
A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans
G. L. Bond et al.
ONCOGENE (2007)
MDM2 SNP309 accelerates colorectal tumour formation in women
Gareth L. Bond et al.
JOURNAL OF MEDICAL GENETICS (2006)
MDM2 gene promoter polymorphisms and risk of lung cancer:: a case-control analysis
Guojun Li et al.
CARCINOGENESIS (2006)
Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer
Helge Lind et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner
Gareth L. Bond et al.
CANCER RESEARCH (2006)
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
GL Bond et al.
CELL (2004)
Ligand-, cell-, and estrogen receptor subtype (α/β)-dependent activation at GC-rich (Sp1) promoter elements
B Saville et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
